back to Meetings page
- IMMPACT-XIX Slide Presentations
- 1. Precision pain medicine: accomplishments of the past 25 years, and prospects for the next 10
- Clifford Woolf, MD, PhD
- 2. Preclinical research obstacles and opportunities in developing precision pain medicine: an overview
- Andrew Rice, MBBS, MD
- 3. Clinical research obstacles and opportunities in developing precision pain medicine: an overview
- Michael Rowbotham, MD
- 4. Precision medicine at the NIH
- William Riley, PhD
- 5. Rare vs. common gene variants as guides to pain mechanisms and drug development
- Alban Latremoliere, PhD
- 6. Sodium channels as targets for precision pain medicine: preclinical perspectives
- Simon Tate, PhD
- 7. Sodium channels as targets for precision pain medicine: "irritable nociceptors" and other phenotypes in the design of clinical trials
- Troels Jensen, MD, PhD
- 8. COX inhibitors and NGF antibodies as targets for precision pain medicine
- Nathaniel Katz, MD
- 9. Descending inhibition as a target for precision pain medicine
- Roland Staud, MD
- 10. Signs, symptoms, and comprehensive QST: a perspective from the German Research Network on Neuropathic Pain
- Ralf Baron, MD
- 11. Signs, symptoms, and bedside QST: α2-δ and other targets
- Roy Freeman, MD
- 12. Non-pharmacologic treatments in precision pain medicine: rationale for splitting (stratifying) vs. lumping
- Dennis Turk, PhD
- 13. What else needs to be included when phenotyping is considered?
- Robert Edwards, PhD